Skip to Content
Merck
  • In vivo synaptic scaling is mediated by GluA2-lacking AMPA receptors in the embryonic spinal cord.

In vivo synaptic scaling is mediated by GluA2-lacking AMPA receptors in the embryonic spinal cord.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2013-04-19)
Miguel Angel Garcia-Bereguiain, Carlos Gonzalez-Islas, Casie Lindsly, Ellie Butler, Atlantis Wilkins Hill, Peter Wenner
ABSTRACT

When spiking activity within a network is perturbed for hours to days, compensatory changes in synaptic strength are triggered that are thought to be important for the homeostatic maintenance of network or cellular spiking activity. In one form of this homeostatic plasticity, called synaptic scaling, all of a cell's AMPAergic miniature postsynaptic currents (mEPSCs) are increased or decreased by some scaling factor. Although synaptic scaling has been observed in a variety of systems, the mechanisms that underlie AMPAergic scaling have been controversial. Certain studies find that synaptic scaling is mediated by GluA2-lacking calcium receptors (CP-AMPARs), whereas others have found that scaling is mediated by GluA2-containing calcium-impermeable receptors (CI-AMPARs). Spontaneous network activity is observed in most developing circuits, and in the spinal cord this activity drives embryonic movements. Blocking spontaneous network activity in the chick embryo by infusing lidocaine in vivo triggers synaptic scaling in spinal motoneurons; here we show that AMPAergic scaling occurs through increases in mEPSC conductance that appear to be mediated by the insertion of GluA2-lacking AMPA receptors at the expense of GluA2-containing receptors. We have previously reported that in vivo blockade of GABAA transmission, at a developmental stage when GABA is excitatory, also triggered AMPAergic synaptic scaling. Here, we show that this form of AMPAergic scaling is also mediated by CP-AMPARs. These findings suggest that AMPAergic scaling triggered by blocking spiking activity or GABAA receptor transmission represents similar phenomena, supporting the idea that activity blockade triggers scaling by reducing GABAA transmission.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine hydrochloride monohydrate, solid
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
SR-95531, ≥98% (HPLC), powder